Compare DexCom, Inc. (DXCM) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Keysight Technologies Inc — how do they compare? DexCom, Inc. trades at $77.54 (market cap $28.06B), while Keysight Technologies Inc trades at $313.15 (market cap $55.15B). The key difference: Keysight Technologies Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| DXCM | KEYS | |
|---|---|---|
Market Cap | $28.06B | $55.15B |
Sector | Health | Technology |
52-Week High | $89.53 | $373.34 |
52-Week Low | $54.84 | $158.51 |
Enterprise Value | $27.03B | $55.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Keysight Technologies (KEYS) trades at $325.73, up 1.53% today, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.87 exceeding the $2.32 estimate. Revenue for 2025 was $5.38 billion, with a net income margin of 15.81%. Recent news highlights expansion in 5G, cybersecurity testing, and photonics design automation through acquisitions and partnerships.
The outlook is positive, supported by analyst consensus with an 81.25% buy rating and a $396.56 price target, implying 22% upside. Risks include high valuation multiples, such as a P/E of 51.97, and volatile cash flow trends, with net cash flow turning negative in 2026. Growth drivers include AI-driven data center demand and 5G network expansion, but execution on investments remains key.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
